Qin Fengming, Ren Ning, Cheng Wenyu, Wei Heng
Chengdu Kanghua Biological Products Co., Ltd., Chengdu 611130, Sichuan, China.
Sheng Wu Gong Cheng Xue Bao. 2023 Oct 25;39(10):3966-3984. doi: 10.13345/j.cjb.230273.
Messenger RNA (mRNA) vaccines emerge as promising vaccines to prevent infectious diseases. Compared with traditional vaccines, mRNA vaccines present numerous advantages, such as high potency, safe administration, rapid production potentials, and cost-effective manufacturing. In 2020, two COVID-19 vaccines (BNT162b2 and mRNA-1273) were approved by the Food and Drug Administration (FDA). The two vaccines showed high efficiency in combating COVID-19, which indicates the great advantages of mRNA technology in developing vaccines against emergent infectious diseases. Here, we summarize the type, immune mechanisms, modification methods of mRNA vaccines, and their applications in preventing infectious diseases. Current challenges and future perspectives in developing mRNA vaccines are also discussed.
信使核糖核酸（mRNA）疫苗成为预防传染病的有前景的疫苗。与传统疫苗相比，mRNA疫苗具有许多优势，如高效力、安全给药、快速生产潜力和具有成本效益的制造。2020年，两种新冠病毒疫苗（BNT162b2和mRNA-1273）获得美国食品药品监督管理局（FDA）批准。这两种疫苗在抗击新冠病毒方面显示出高效性，这表明mRNA技术在开发针对新发传染病的疫苗方面具有巨大优势。在此，我们总结了mRNA疫苗的类型、免疫机制、修饰方法及其在预防传染病中的应用。还讨论了开发mRNA疫苗当前面临的挑战和未来前景。
